India Pharma Outlook Team | Wednesday, 04 November 2026
STAT6 degrader development has faced a setback after Sanofi decided to discontinue its experimental autoimmune disease drug program with Nurix Therapeutics.
Sanofi ended the development program of SAR448272, an oral drug candidate undergoing Phase 1 clinical evaluation.
The decision also removes Nurix's eligibility for potential future development, regulatory and commercial milestone payments and royalties associated with the program.
The development follows an August 2026 milestone payment linked to the candidate's entry into clinical testing.
Beyond its financial implications, the discontinuation draws attention to the challenges of advancing targeted protein degradation technologies into clinical development for autoimmune and inflammatory diseases.
The company has not publicly disclosed a specific reason for the decision, and no clinical safety or efficacy failure has been established. SAR448272, also identified as NX-3911, was developed as an oral STAT6 degrader for type 2 inflammatory diseases.
STAT6 is a signaling protein involved in immune responses and the regulation of inflammatory pathways. Its role in immune signaling has made it a potential therapeutic target for conditions associated with type 2 inflammation.
The decision marks a reversal for the program, which entered clinical development in August 2026. At that time, Nurix announced that it had received a USD 10 million milestone payment after Sanofi initiated the Phase 1 trial.
The candidate's discontinuation approximately three months later highlights the uncertainty associated with early-stage pharmaceutical research and development.
Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future
The discontinued program represents a significant loss of potential revenue for Nurix Therapeutics. In its October 2026 quarterly update, the company reported that it had earned approximately USD 139 million under its Sanofi collaboration.
Nurix remained eligible for around USD 455 million in future milestone payments associated with the STAT6 program, in addition to potential royalties.
The development also illustrates the financial exposure associated with pharmaceutical R&D partnerships, where biotech companies may depend on development milestones and licensing agreements to monetize experimental drug candidates.
Despite the setback, Nurix continues to advance other programs based on targeted protein degradation and related drug discovery approaches.
Its clinical-stage pipeline includes bexobrutideg, a BTK degrader being developed with Roche, and GS-6791/NX-0479, an IRAK4 degrader being investigated with Gilead for rheumatoid arthritis.
The company is also advancing NX-1607, a wholly owned CBL-B inhibitor, through Phase 1b clinical cohorts for multiple cancer indications.
The Sanofi decision does not terminate the entire collaboration.
In 2025, Sanofi had exercised a license extension option covering two programs targeting transcription factors for autoimmune and inflammatory diseases, including STAT6 and another undisclosed target.
Nurix CEO Arthur T. Sands said the company remained well-positioned despite the discontinuation, pointing to its substantial cash reserves, three clinical-stage programs and preclinical pipeline.
.jpg)
